LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
—Julie Gould (Mazurkiewicz)
LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
—Julie Gould (Mazurkiewicz)
LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
In a recent interview, Dr Jonathan Silverberg, mentioned the importance of understanding the strengths and weaknesses of new therapies. Which aspect did he particularly emphasize as crucial in clinical practice?
In a recent interview, Dr Jonathan Silverberg, mentioned the importance of understanding the strengths and weaknesses of new therapies. Which aspect did he particularly emphasize as crucial in clinical practice?
Researchers aimed to investigate the relationship between insulin use, social determinants of health, and non-melanoma skin cancer risk among individuals with diabetes.
Researchers aimed to investigate the relationship between insulin use, social determinants of health, and non-melanoma skin cancer risk among individuals with diabetes.
The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galderma.com/us/preboard-webinar.
The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galderma.com/us/preboard-webinar.
There are many new devices available to target the aftereffects of acne, allowing dermatologists to tailor treatment plans for the best possible patient outcomes.
There are many new devices available to target the aftereffects of acne, allowing dermatologists to tailor treatment plans for the best possible patient outcomes.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Test your knowledge of the epidemiologic data examining environmental exposures and their association with atopic disease development. This quiz explores key population-level observations shaping modern allergy research.
Test your knowledge of the epidemiologic data examining environmental exposures and their association with atopic disease development. This quiz explores key population-level observations shaping modern allergy research.
